Impaired Coronary Vasodilator Reserve and Adverse Prognosis in Patients With Systemic Inflammatory Disorders.

[1]  R. Blankstein,et al.  Coronary microvascular dysfunction in patients with psoriasis , 2020, Journal of Nuclear Cardiology.

[2]  R. Blankstein,et al.  Hypertensive coronary microvascular dysfunction: a subclinical marker of end organ damage and heart failure. , 2020, European heart journal.

[3]  C. Russo,et al.  Myocardial Microvascular Dysfunction in Rheumatoid Arthritis: Quantitation by 13N-Ammonia Positron Emission Tomography/Computed Tomography , 2019, Circulation. Cardiovascular imaging.

[4]  Rahul C. Deo,et al.  Coronary Microvascular Dysfunction, Left Ventricular Remodeling, and Clinical Outcomes in Patients With Chronic Kidney Impairment , 2019, Circulation.

[5]  R. Diaz,et al.  Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. , 2019, The New England journal of medicine.

[6]  K. Liao,et al.  Coronary Microvascular Dysfunction in Rheumatoid Arthritis Compared to Diabetes Mellitus and Association With All‐Cause Mortality , 2019, Arthritis care & research.

[7]  F. Tona,et al.  Inflammation and Coronary Microvascular Dysfunction in Autoimmune Rheumatic Diseases , 2019, International journal of molecular sciences.

[8]  A. Khera,et al.  2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2019, Journal of the American College of Cardiology.

[9]  Kristian Thygesen,et al.  Fourth Universal Definition of Myocardial Infarction (2018). , 2018, Journal of the American College of Cardiology.

[10]  M. Kaplan,et al.  Cardiovascular disease in systemic lupus erythematosus: an update , 2018, Current opinion in rheumatology.

[11]  W. Boehncke,et al.  The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond , 2018, Front. Immunol..

[12]  Akshay S. Desai,et al.  Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction , 2018, European heart journal.

[13]  Deepak L. Bhatt,et al.  Integrated Noninvasive Physiological Assessment of Coronary Circulatory Function and Impact on Cardiovascular Mortality in Patients With Stable Coronary Artery Disease , 2017, Circulation.

[14]  R. Blankstein,et al.  Coronary Microvascular Dysfunction Identifies Patients at High Risk of Adverse Events Across Cardiometabolic Diseases. , 2017, Journal of the American College of Cardiology.

[15]  A. Saltiel,et al.  Adapting to obesity with adipose tissue inflammation , 2017, Nature Reviews Endocrinology.

[16]  P. Libby,et al.  Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease , 2017, The New England journal of medicine.

[17]  Katherine P Liao,et al.  Cardiovascular disease in patients with rheumatoid arthritis. , 2017, Trends in cardiovascular medicine.

[18]  N. Mehta,et al.  The Link Between Inflammatory Disorders and Coronary Heart Disease: a Look at Recent Studies and Novel Drugs in Development , 2016, Current Atherosclerosis Reports.

[19]  Eric E. Smith,et al.  2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). , 2015, Circulation.

[20]  R. Blankstein,et al.  Interaction of Impaired Coronary Flow Reserve and Cardiomyocyte Injury on Adverse Cardiovascular Outcomes in Patients Without Overt Coronary Artery Disease , 2015, Circulation.

[21]  J. Polak,et al.  Systemic inflammation and cardiovascular risk factors predict rapid progression of atherosclerosis in rheumatoid arthritis , 2014, Annals of the rheumatic diseases.

[22]  A. Armstrong,et al.  Psoriasis and Major Adverse Cardiovascular Events: A Systematic Review and Meta‐Analysis of Observational Studies , 2013, Journal of the American Heart Association.

[23]  Andrea B Troxel,et al.  Increased risk of diabetes mellitus and likelihood of receiving diabetes mellitus treatment in patients with psoriasis. , 2012, Archives of dermatology.

[24]  P. Libby.  Inflammation in Atherosclerosis , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[25]  A. Giovagnoni,et al.  Impaired coronary flow reserve in young patients affected by severe psoriasis. , 2012, Atherosclerosis.

[26]  B. Hahn,et al.  Accelerated atherosclerosis in patients with SLE—mechanisms and management , 2012, Nature Reviews Rheumatology.

[27]  M. Pencina,et al.  Improved Cardiac Risk Assessment With Noninvasive Measures of Coronary Flow Reserve , 2011, Circulation.

[28]  Andrea B Troxel,et al.  Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. , 2010, European heart journal.

[29]  I. Kohane,et al.  Electronic medical records for discovery research in rheumatoid arthritis , 2010, Arthritis care & research.

[30]  Paul M Ridker,et al.  Inflammation in atherosclerosis: from pathophysiology to practice. , 2009, Journal of the American College of Cardiology.

[31]  M. Rubens,et al.  Chronic inflammation and coronary microvascular dysfunction in patients without risk factors for coronary artery disease. , 2009, European heart journal.

[32]  Georges El Fakhri,et al.  Reproducibility and Accuracy of Quantitative Myocardial Blood Flow Assessment with 82Rb PET: Comparison with 13N-Ammonia PET , 2009, Journal of Nuclear Medicine.

[33]  P. Sidiropoulos,et al.  Sustained improvement of vascular endothelial function during anti‐TNFα treatment in rheumatoid arthritis patients , 2009, Scandinavian journal of rheumatology.

[34]  Ran Klein,et al.  Quantification of myocardial blood flow with 82Rb dynamic PET imaging , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[35]  D. Isenberg,et al.  Cytokines and systemic lupus erythematosus , 2000, Annals of the rheumatic diseases.

[36]  M. Hochberg,et al.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. , 1997, Arthritis and rheumatism.

[37]  A. Morise,et al.  Development and validation of a clinical score to estimate the probability of coronary artery disease in men and women presenting with suspected coronary disease. , 1997, The American journal of medicine.

[38]  M. Petri,et al.  Risk factors for coronary artery disease in patients with systemic lupus erythematosus. , 1992, The American journal of medicine.

[39]  J F Fries,et al.  The 1982 revised criteria for the classification of systemic lupus erythematosus. , 1982, Arthritis and rheumatism.

[40]  D. Berman,et al.  Myocardial ischemia in the absence of obstructive coronary artery disease in systemic lupus erythematosus. , 2011, JACC. Cardiovascular imaging.

[41]  M. Feldmann,et al.  Cytokines in autoimmune disorders. , 1998, International reviews of immunology.